4Nong Z,Stassen JM,Moons L,et al.Inhibition of tissue angiotensin-converting enzymewith quinapril reduces hypoxic pulmonary hypertension and pulmonary vascularremodeling.Circulation,1996;94:1941～1947
5Sfinkakis PP,Kyriakidis MK,Vergos CG,et al.Cardiopulmonary henodynamics in systemicsclerosis and respones to nifedipine and captopril.Am J Med,1991;90:541～546
2Galie N, Manes A, Branzi A, et al. The endothelin system in pulmonary arterial hypertension[J]. Cardiovasc Res,2004,61(3):227-237.
3Wang DL, Tang CC, Wang BS, et al. Cyclical strain increase endothelin-1 secretion and gene expression in human endothelial cells[J]. Biophys Res Commun. 1993,195(2) : 1050.
4Rerolle JP, Hertig A, Nguyen C, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis[ J]. Kidney Int, 2000,58(5) :1841-1850.
5Jem S. Endothelium-dependent vasodilation and tissue-type plasminogen activator relessein borderline hypertension [J]. Arteroscler Thromb Vasc Biol, 1997,17(2) : 3376-3381.
6Eitzman DT, Westrick RJ,Nabel EG, et al. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice [ J].Blood,2000,95 (2) :577-580.
7Aidan P, Sharma R, Paul R, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease[ J ]. Circulation, 2002,106(4) : 92-99.
8Dietz R, von-Harsdorf R, Gross M, et al. Angiotensin Ⅱ and coronary artery disease, congestive heart failure and sudden cardiac death [ J ].Basic Res Cardiol, 1998,93[Suppl 2] :s101-108.
9Chung O, Csikos T, Unger T. Angiotensin Ⅱ receptor pharmacology and AT2 receptors C [J]. J Hum Hypertens, 1999,12[ Suppl 1 ] : S11-20.
10Jalowy A, Schulz R, Dorge H, et al.Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-roceptor activation,bradykinin and prostaglandings in pigs[J].J Am Coll Cardiol,2003,32(6) : 1787-1796.
